Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-11346
Bodmer, N; Walters, D K; Fuchs, B (2008). Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatric Blood & Cancer, 50(4):905-908.
|PDF - Registered users only|
The folate inhibitor methotrexate (MTX) is an important component of osteosarcoma (OS) treatment regimens. New generation multitargeted antifolates, such as pemetrexed (PMX), have shown promise in the treatment of various solid tumors. In this study, the in vitro efficacy of MTX and PMX was compared in OS cell lines. MTX demonstrated a superior cytotoxic effect in comparison to PMX in all tested cell lines. Apoptosis assays revealed that both MTX and PMX induce apoptosis but MTX demonstrated superior efficacy. These in vitro results suggest that PMX as a single agent may not demonstrate improved efficacy compared to MTX in OS patients.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Balgrist University Hospital, Swiss Spinal Cord Injury Center|
|DDC:||610 Medicine & health|
|Deposited On:||23 Jan 2009 13:39|
|Last Modified:||27 Nov 2013 19:34|
|Additional Information:||Wiley – Full text available online|
|Citations:||Web of Science®. Times Cited: 2|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page